These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 22701615)

  • 1. Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer.
    Meyerhardt JA; Ancukiewicz M; Abrams TA; Schrag D; Enzinger PC; Chan JA; Kulke MH; Wolpin BM; Goldstein M; Blaszkowsky L; Zhu AX; Elliott M; Regan E; Jain RK; Duda DG
    PLoS One; 2012; 7(6):e38231. PubMed ID: 22701615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status.
    Kang MJ; Hong YS; Kim KP; Kim SY; Baek JY; Ryu MH; Lee JL; Chang HM; Kim MJ; Chang HJ; Kang YK; Kim TW
    Invest New Drugs; 2012 Aug; 30(4):1607-13. PubMed ID: 21706149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma.
    Folprecht G; Lutz MP; Schöffski P; Seufferlein T; Nolting A; Pollert P; Köhne CH
    Ann Oncol; 2006 Mar; 17(3):450-6. PubMed ID: 16303861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integration of novel agents in the treatment of colorectal cancer.
    Iqbal S; Lenz HJ
    Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan.
    Loupakis F; Cremolini C; Fioravanti A; Orlandi P; Salvatore L; Masi G; Schirripa M; Di Desidero T; Antoniotti C; Canu B; Faviana P; Sensi E; Lupi C; Fontanini G; Basolo F; Di Paolo A; Danesi R; Falcone A; Bocci G
    Target Oncol; 2014 Sep; 9(3):205-14. PubMed ID: 23821377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicenter Phase II study of cetuximab plus irinotecan in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin and fluoropyrimidines.
    Tahara M; Shirao K; Boku N; Yamaguchi K; Komatsu Y; Inaba Y; Arai T; Mizunuma N; Satoh T; Takiuchi H; Nishina T; Sakata Y
    Jpn J Clin Oncol; 2008 Nov; 38(11):762-9. PubMed ID: 18836202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer.
    Folprecht G; Hamann S; Schütte K; Trarbach T; Stoehlmacher-Williams J; Ehninger G
    BMC Cancer; 2014 Jul; 14():521. PubMed ID: 25038824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cetuximab plus irinotecan in pretreated metastatic colorectal cancer patients: the ELSIE study.
    Lim R; Sun Y; Im SA; Hsieh RK; Yau TK; Bonaventura A; Cheirsilpa A; Esser R; Mueser M; Advani S
    World J Gastroenterol; 2011 Apr; 17(14):1879-88. PubMed ID: 21528063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
    Cunningham D; Humblet Y; Siena S; Khayat D; Bleiberg H; Santoro A; Bets D; Mueser M; Harstrick A; Verslype C; Chau I; Van Cutsem E
    N Engl J Med; 2004 Jul; 351(4):337-45. PubMed ID: 15269313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial.
    Vincenzi B; Santini D; Rabitti C; Coppola R; Beomonte Zobel B; Trodella L; Tonini G
    Br J Cancer; 2006 Mar; 94(6):792-7. PubMed ID: 16508634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study.
    Tabernero J; Ciardiello F; Rivera F; Rodriguez-Braun E; Ramos FJ; Martinelli E; Vega-Villegas ME; Roselló S; Liebscher S; Kisker O; Macarulla T; Baselga J; Cervantes A
    Ann Oncol; 2010 Jul; 21(7):1537-1545. PubMed ID: 19940007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase 1 study combining the HER3 antibody seribantumab (MM-121) and cetuximab with and without irinotecan.
    Cleary JM; McRee AJ; Shapiro GI; Tolaney SM; O'Neil BH; Kearns JD; Mathews S; Nering R; MacBeath G; Czibere A; Sharma S; Korn WM
    Invest New Drugs; 2017 Feb; 35(1):68-78. PubMed ID: 27853996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study.
    Raoul JL; Van Laethem JL; Peeters M; Brezault C; Husseini F; Cals L; Nippgen J; Loos AH; Rougier P
    BMC Cancer; 2009 Apr; 9():112. PubMed ID: 19366444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer.
    Garm Spindler KL; Pallisgaard N; Rasmussen AA; Lindebjerg J; Andersen RF; Crüger D; Jakobsen A
    Ann Oncol; 2009 May; 20(5):879-84. PubMed ID: 19179548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines.
    Shitara K; Yuki S; Yoshida M; Takahari D; Utsunomiya S; Yokota T; Sato Y; Inaba Y; Tajika M; Kawai H; Yamaura H; Kato M; Yamazaki K; Komatsu Y; Muro K
    Invest New Drugs; 2012 Apr; 30(2):787-93. PubMed ID: 21174225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of cetuximab/irinotecan in chemotherapy-refractory metastatic colorectal adenocarcinomas: a clinical practice setting, multicenter experience.
    Gebbia V; Del Prete S; Borsellino N; Ferraù F; Tralongo P; Verderame F; Leonardi V; Capasso E; Maiello E; Bordonaro R; Stinco S; Agostara B; Barone C
    Clin Colorectal Cancer; 2006 Mar; 5(6):422-8. PubMed ID: 16635281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer.
    Azad N; Dasari A; Arcaroli J; Taylor GE; Laheru DA; Carducci MA; McManus M; Quackenbush K; Wright JJ; Hidalgo M; Diaz LA; Donehower RC; Zhao M; Rudek MA; Messersmith WA
    Invest New Drugs; 2013 Apr; 31(2):345-54. PubMed ID: 22615057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A triplet combination with capecitabine/oxaliplatin/irinotecan (XELOXIRI) plus cetuximab as first-line therapy for patients with metastatic colorectal cancer: a dose escalation study.
    Sato Y; Hirakawa M; Ohnuma H; Takahashi M; Okamoto T; Okamoto K; Miyamoto H; Muguruma N; Furuhata T; Takemasa I; Kato J; Takayama T
    Cancer Chemother Pharmacol; 2017 Dec; 80(6):1133-1139. PubMed ID: 29038850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EGFR related mutational status and association to clinical outcome of third-line cetuximab-irinotecan in metastatic colorectal cancer.
    Spindler KL; Pallisgaard N; Lindebjerg J; Frifeldt SK; Jakobsen A
    BMC Cancer; 2011 Mar; 11():107. PubMed ID: 21439039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of combination chemotherapy with irinotecan and cetuximab for pretreated metastatic colorectal cancer harboring wild-type KRAS.
    Shitara K; Yokota T; Takahari D; Shibata T; Ura T; Utsunomiya S; Inaba Y; Yamaura H; Sato Y; Najima M; Kawai H; Tajika M; Sawaki A; Yatabe Y; Muro K
    Invest New Drugs; 2011 Aug; 29(4):688-93. PubMed ID: 20072801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.